Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab versus obinutuzumab effects on lymphocyte subsets in SLE
NL-OMON56559Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rituximab, obinutuzumab and methylprednisolone, sponsored by Amsterdam University Medical Center. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
rituximabobinutuzumabmethylprednisolone
Beyond the preview
Go deeper on NL-OMON56559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56559.